Trial Profile
Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Cisplatin
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 19 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Aug 2021.
- 26 Jan 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.
- 26 Jan 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Apr 2021.